Epilepsy in pregnancy and contraception

01Role and principlesWho benefits and the main preventive aims.

Preconception care aims to achieve the best attainable seizure control on the safest effective regimen before organogenesis. Review whether epilepsy and seizure classification remain secure, how long seizure freedom has lasted, previous medicine failures, dose, adherence and SUDEP risk. Explain known and uncertain fetal effects in absolute terms where reliable data exist. A planned change may take months because cross-titration must preserve control; contraception therefore remains important until the new regimen is stable and specialist review is complete.

Contraception cannot be separated from pharmacology. Carbamazepine, phenytoin, phenobarbital, primidone, oxcarbazepine and some topiramate exposure can induce metabolism and impair selected hormonal methods. Long-acting intrauterine contraception and depot medroxyprogesterone are not affected in the same way, but suitability is individual. Combined oestrogen-containing contraception can substantially lower lamotrigine levels and concentrations may rise during the hormone-free interval. Emergency contraception after enzyme-inducing medication requires same-day FSRH-aligned advice, with a copper intrauterine device often the most effective unaffected option.

During pregnancy, vomiting, adherence, sleep loss and altered drug clearance can destabilise control. Antenatal teams should agree who reviews seizure frequency and levels, how doses change and how postpartum de-escalation will occur. Birth usually follows obstetric indications, with regular medicine continued and an acute seizure plan available. Current MHRA materials, UK Teratology Information Service advice, BNF dosing and local maternal-medicine pathways should guide management.

Key points

Discuss pregnancy and contraception from the time antiseizure treatment is considered, because unplanned conception and interactions can occur years before someone volunteers a pregnancy intention.
Refer anyone with epilepsy who is pregnant or planning pregnancy to an epilepsy specialist team and coordinate decisions with specialist obstetric, primary-care and pharmacy services.
Do not stop antiseizure medicine abruptly after a positive pregnancy test; uncontrolled bilateral tonic-clonic seizures can harm both pregnant person and fetus, so changes require urgent specialist balancing.
Use effective monotherapy at the lowest dose that maintains control where feasible, but avoid destabilising a previously successful regimen solely to meet a simplistic dose target.
Valproate has major congenital and neurodevelopmental risks and requires the Pregnancy Prevention Programme for women and girls able to become pregnant; topiramate now has its own UK Pregnancy Prevention Programme.
Offer high-dose folic acid—commonly 5 mg daily on prescription—before conception and through the first 12 weeks in line with the person’s UK preconception plan, while recognising it does not remove medicine-related risk.
Pregnancy can increase clearance of medicines including lamotrigine and levetiracetam; a preconception baseline concentration and symptom-led serial levels can guide dose adjustment, followed by postpartum reduction when clearance normalises.
Enzyme-inducing antiseizure medicines can reduce hormonal contraceptive effectiveness, while oestrogen-containing contraception can lower lamotrigine exposure; check a current interaction resource for every combination.
NICE supports breastfeeding when desired after an individual medicine review, with observation of the infant and a plan for parental sleep and nocturnal seizure safety.

02Assessment and patient selectionRisk features, eligibility and important cautions.

Preconception opportunity

A contraception review, annual epilepsy appointment, new relationship or request for folic acid should prompt early discussion of medicine risk and specialist planning before conception.

Breakthrough during pregnancyRed flag

New seizures can follow falling drug concentrations, vomiting, missed doses, sleep deprivation or pregnancy-specific pathology and need prompt multidisciplinary assessment rather than automatic dose escalation.

Eclampsia differentialRed flag

A seizure after 20 weeks or postpartum, particularly with hypertension, headache, visual symptoms, epigastric pain or proteinuria, requires immediate obstetric treatment even in someone with established epilepsy.

Contraceptive interaction

Breakthrough bleeding, starting or stopping an enzyme inducer, or changing an oestrogen-containing method can signal altered contraceptive or lamotrigine exposure and needs timely specialist pharmacy advice.

Postpartum vulnerability

Rapid pharmacokinetic reversal, sleep deprivation, missed medicines and unsupervised bathing or carrying can combine after birth, making a written dose and infant-safety plan essential.

03Baseline assessmentMeasurements that guide the plan and track progress.

Investigation order

Read from the initial assessment onwards. Tests may run in parallel in urgent care; first-line, preferred, confirmatory, definitive and gold-standard labels appear only when the chapter explicitly states them.

01
Preconception medication and syndrome reviewFirst step
Why
Confirm the indication and identify a safer effective regimen before pregnancy begins.
Interpretation and limitations
Document seizure types, control, previous failures, exact dose, interactions and regulatory status. A medicine change is justified only when expected reproductive benefit outweighs destabilisation risk.
02
Baseline and serial antiseizure concentrations
Why
Create an individual reference and identify clinically meaningful pharmacokinetic decline during pregnancy.
Interpretation and limitations
NICE particularly highlights medicines such as lamotrigine, levetiracetam, carbamazepine, oxcarbazepine, phenobarbital and phenytoin. Interpret levels with adherence, seizure control and adverse effects, not as automatic dose commands.
03
Pregnancy and antenatal assessment
Why
Date pregnancy, identify obstetric risk and coordinate screening or fetal surveillance through specialist care.
Interpretation and limitations
Routine and additional surveillance follow obstetric and fetal-medicine advice; normal imaging cannot remove neurodevelopmental uncertainty from some exposures. Report suspected medicine-related adverse outcomes through appropriate systems.
04
Contraception interaction check
Why
Verify that both contraceptive efficacy and antiseizure exposure remain acceptable for the exact medicines and doses.
Interpretation and limitations
Use current FSRH, BNF and MHRA resources. Do not extrapolate from one progestogen or one dose of topiramate to all methods; document what will happen if either medicine changes.
05
Acute seizure work-up in pregnancy
Why
Separate breakthrough epilepsy from eclampsia and other neurological or metabolic emergencies.
Interpretation and limitations
Check observations, glucose, urine protein and context-directed bloods and imaging while obstetric and neurological teams assess. Necessary CT or MRI should not be withheld through an exaggerated perception of fetal imaging risk.

04InterventionsLifestyle, treatment and escalation options.

01Before pregnancyOptimise before conceptionFirst stepA person with epilepsy could become pregnant or is planning pregnancy.

11. Refer early to epilepsy specialists, confirm seizure and syndrome diagnosis, and review control, prior drug failures, current dose and reproductive safety.
22. If a safer effective regimen is available, complete cautious cross-titration and demonstrate stability before stopping contraception or attempting conception.
33. Prescribe high-dose folic acid according to current UK preconception advice and address smoking, alcohol, sleep, vaccinations and other medicines.
44. Agree baseline drug levels where useful, contraception during transition and who to contact immediately after a positive pregnancy test.

02During pregnancyPreserve control while exposure changesPregnancy is confirmed in a person taking antiseizure medication.

11. Advise continuation of regular medicine pending urgent specialist review; record seizures, adherence, vomiting and the exact regimen without blame.
22. Coordinate epilepsy and specialist obstetric care, explaining risks of both seizures and fetal medicine exposure through shared, documented decisions.
33. Monitor clinically and use individual baseline concentrations for selected agents, adjusting dose only with a plan to prevent toxicity after delivery.
44. Prepare birth, prolonged-seizure rescue and postnatal plans, including regular dosing during labour, sleep support, breastfeeding and infant-handling safety.

03ContraceptionPrevent bidirectional interactionsStarting, stopping or changing either an antiseizure medicine or a contraceptive method.

11. Identify enzyme-inducing properties, teratogenic regulatory requirements and whether hormonal contraception changes the antiseizure medicine concentration.
22. Offer methods unaffected by the interaction where acceptable and arrange specialist contraception advice for valproate or topiramate Pregnancy Prevention Programme compliance.
3Alternative3. Explain additional or alternative protection, expected bleeding changes and what to do after missed contraception or unprotected intercourse using current FSRH guidance.
44. Recheck seizure control and adverse effects after any hormonal transition, especially with lamotrigine, and record an interaction plan in both clinical records.

05Medicines and treatment safetyRegimens, contraindications and review points.

Supports neural-tube development as part of preconception care, although it cannot neutralise the congenital or neurodevelopmental risks of a high-risk antiseizure medicine.

Folic acid

UK practice commonly prescribes 5 mg orally once daily before conception and until 12 weeks of pregnancy for people taking antiseizure medicines; confirm timing and duration in the current specialist plan.

Start before pregnancy where possible and do not delay epilepsy review. Confirm ongoing need after 12 weeks, check other supplements to avoid duplication and explain that adherence to antiseizure treatment remains important.

Often selected for focal or some generalised epilepsies because available pregnancy safety data are more reassuring than for valproate, provided it controls the person’s syndrome.

Lamotrigine in pregnancy

Continue the individually effective divided dose; obtain a preconception reference when monitoring is planned and adjust in specialist care against seizures and concentration change rather than a universal target.

Clearance commonly rises during pregnancy and returns rapidly postpartum, creating breakthrough then toxicity risks. Oestrogen contraception also lowers exposure; titration and rash precautions remain essential.

May control selected difficult epilepsies but carries fetal growth, congenital and potential neurodevelopmental harms that materially restrict use.

Topiramate under Pregnancy Prevention Programme

Use only for epilepsy in pregnancy when there is no suitable alternative, and in women or girls able to become pregnant only when all current Pregnancy Prevention Programme conditions are fulfilled.

Ensure highly effective contraception, pregnancy exclusion before initiation and documented annual review. It can interact with hormonal contraception; after a positive pregnancy test for epilepsy, obtain urgent advice and do not stop abruptly.

06Targets, monitoring and follow-upResponse, safety and longer-term review.

Track every seizure type, adherence, vomiting, sleep and injuries through pregnancy, escalating any bilateral tonic-clonic recurrence or material change promptly.
Where level monitoring is chosen, compare against the individual preconception baseline and document dose changes with a specific postpartum reversal plan.
Review contraception effectiveness and interaction whenever a medicine or dose changes, and audit completion of current valproate or topiramate safety documentation.
Coordinate antenatal and fetal assessment through specialist obstetrics while avoiding false reassurance or alarm from screening that cannot answer every neurodevelopmental question.
After birth, assess maternal sedation, infant feeding and alertness, medication adherence, seizure safety and restoration of pre-pregnancy doses as clearance normalises.

07Special situationsVariants, exceptions and circumstances that change the usual approach.

Control is reproductive safety

Avoiding teratogenic exposure matters, but destabilising effective therapy can produce tonic-clonic seizures, trauma, hypoxia and SUDEP risk; both sides belong in the same decision.

Interactions run both ways

An inducer may reduce hormonal contraceptive protection, while an oestrogen-containing method may reduce lamotrigine concentration and alter seizure control.

Baseline levels are personal

A concentration associated with seizure freedom before conception can guide pregnancy adjustment more usefully than chasing a generic reference range.

Delivery is usually obstetric-led

Epilepsy alone does not dictate caesarean birth, but regular dosing, hydration, sleep, analgesia and an emergency plan should be protected around labour.

Postpartum planning starts antenatally

The safest plan anticipates rapid medicine-clearance changes, fragmented sleep and practical risks such as bathing or carrying an infant if awareness could be lost.

08Common pitfallsFrequent interpretation and management errors.

01
Telling someone to stop valproate, topiramate or another antiseizure medicine immediately after a positive test can precipitate dangerous breakthrough seizures.
02
Assuming all hormonal contraception works normally with every antiseizure medicine risks both unintended pregnancy and altered seizure control.
03
Waiting until pregnancy to change a stable complex regimen compresses titration into the period when both seizures and fetal exposure are most consequential.
04
Increasing lamotrigine through pregnancy without a documented postpartum reduction plan can cause dizziness, diplopia and ataxia as clearance returns.
05
Discussing infant malformation risk while omitting maternal SUDEP, driving, sleep and injury risks produces an unbalanced consent conversation.